CA1324051C - Ultrasound enhancement of transdermal drug delivery - Google Patents
Ultrasound enhancement of transdermal drug deliveryInfo
- Publication number
- CA1324051C CA1324051C CA000541496A CA541496A CA1324051C CA 1324051 C CA1324051 C CA 1324051C CA 000541496 A CA000541496 A CA 000541496A CA 541496 A CA541496 A CA 541496A CA 1324051 C CA1324051 C CA 1324051C
- Authority
- CA
- Canada
- Prior art keywords
- ultrasound
- molecules
- skin
- drug
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
Abstract
ULTRASOUND ENHANCEMENT OF TRANSDERMAL DRUG DELIVERY
Abstract of the Invention The present invention is a method using ultrasound to enhance permeation of molecules through the skin and into the blood stream, at a controlled rate. Depending on the drug being infused through the skin, the rate of permeation is increased as well as the efficiency of transfer. Drugs which may not be effective under other conditions, for example, due to degradation within the gastrointestinal tract, can be effectively conveyed transdermally into the circulatory system by means of ultrasound.
Abstract of the Invention The present invention is a method using ultrasound to enhance permeation of molecules through the skin and into the blood stream, at a controlled rate. Depending on the drug being infused through the skin, the rate of permeation is increased as well as the efficiency of transfer. Drugs which may not be effective under other conditions, for example, due to degradation within the gastrointestinal tract, can be effectively conveyed transdermally into the circulatory system by means of ultrasound.
Description
J`l ' ~
ULTRASOUND ENHANCEMENT OF TRANSDERMAL DRUG DELIVERY
~acl;~round o the Invention -This invention is generally in the field of drug delivery and more particularly in the area of ultrasound enhanced and controlled transdermal drug delivery.
Drugs are routinely administered either orally or by injection. The ef~ectiveness of most drugs relies on achieving a certain concentration in the bloodstream. Although some drugs have inherent side effects whlch cannot be eliminated in any dosaye form, many drugs exhibit undesirable behaviors that are specifically related to a particular route of administration.
For example, drugs may be degraded in the GI tract by the low gastric pH, local enzymes or interaction with food or drink within the stomach. The drug or disease itself may forestall or compromise drug absorption because of vomiting or diarrhea. If a drug entity survives its trip through the GI tract, it may face rapid metabolism to pharmacologically inactive forms by the liver, the first-pass effect. Sometimes the drug itself has inherent undesirable attributes such as a short half-life, high potency or a narrow therapeutic blood level range.
Recently, eforts aimed at eliminating some of the problems of traditional dosage forms involve transdermal delivery of the drugs. Topical application has been used for a very long ,, ~ 2 -time, mostly in the treatment of localized skin diseases. Local treatment, however, only requires that the drug permeate the outer layers of the skin to treat the diseased state, with little or no systemic accumulation. Transdermal delivery systems are specifically designed to obtain systemic blood levels. Transdermal permeation or percutaneous absorption can be defined as the passage of a substance, such as a drug, from the outside of the skin through its various layers into the bloodstream.
The transport of drugs through the skin is complex since many factors influence their permeation. These include the skin structure and its properties, the penetrating molecule and its physical-chemical relationship to the skin and the delivery matrix, and the combination of the skin, the penetrant, and the delivery system as a whole.
Topical application of drugs has focused much attention on skin permeability properties. Many reports have described efforts to change skin permeability using chemical enhancers, molecules which enter the stratum corneum and decrease its resistance to drug penetration, or by external means such as iontophoresis~ Chemical agents such as dimethylsulfoxide (DMSO), or 1-dodecylazacycloheptan-2-one (Azone), tend to enhance the penetration of drugs that are incorporated within them. However, in all of these systems, with the exception of iontophoresis, there is no way of externally controlling the rate of drug release.
U.S. Patent No. 4,309,989 to Fahim discloses the topical application of a medication using ultrasound with a coupling agent such as oil.
Ultrasound at a frequency of at least 1000 kHz and a power of one to three W/cm2 was used to cause selective localized intercellular concentration of a zinc containing compound for the treatment of herpes simplex virus. An important limitation of the disclosed method is that it applies only to topical application and intracellular localization of the drug.
As shown in Fig. 1, the skin is a complex structure. There are at least four distinct layers of tissue: the non-viable epidermis (stratum corneum), the viable epidermis, the viable dermis (corium), and the subcutaneous connective tissue thypodermis).
Located within these layers are the skin's circulatory system, the arterial plexus, and appendages, including hair follicles, sebaceous glands and sweat glands. The circulatory system lies in the dermis and tissues below the dermis. Diffusion mechanisms provide for the exchange of nutrients between the epidermis and the blood. The capillaries do not actually enter the epidermal structure but come within 150 to 200 microns of the outer surface of the skin.
As shown in Fig. 1, permeation of the skin can occur by (a) transcellular penetration, through the stratum corneum;
(b) intercellular penetration, through the stratum corneum; and (c) transappendageal penetration, especially including the sebaceous pathway of the pilosebaceous apparatus and the aqueous pathway of the salty sweat glands. The first two mechanisms require further diffusion through the rest of the epidermis and dermis. The third mechanism allows diffusional leakage into the epidermis and direct permeation into the dermis.
X
:
:
Transdermal delivery of drugs has attributes that make it far superior to other modes of systemic drug ~dministration. Despite these advantages, relatively few drugs are deliverable transdermally. The majority of drugs will not penetrate the skin at rates sufficiently high for therapeutic efficacy.
In vitro steady state fluxes of a drug through the skin have ranged as low as .00013 microg/cm2 hr digitoxin to 300 microg/cm2 hr for ephadrine. Several factors on the nature of skin must be considered in determining the degree of transdermal permeation. For example, the type of skin which the substance is to pass through varies from species to species, varies according to age, with the skin of an infant having a greater permeability than that of an older adult, varies according to local composition, thickness and density, varies as a function of injury or exposure to agents such as organic solvents or surfactants, and varies as a function of some diseases such as psoriasis or abrasion. In order to allow clinically useful transdermal application of drugs, some way to enhance and control their rates of penetration must be found.
It is therefore an object of the invention to provide a method for enhancing an controlling permeation of a molecule through the skin and into the circulatory system.
.
1 ", ~ `~
It is a further object of the invention to provide a method for enhancing permeation which operates externally to the skin and does not harm either the skin or the molecules being in~used.
It is still another object of the invention to provide an improved method for transdermal delivery of drugs where the primary goal is to achieve a suitable therapeutic blood level.
It is a further object of the present invention to provide an improved method for transdermal delivery of a drug which is useful with a variety of molecules, including molecules soluble in an aqueous, inorganic or lipid solution.
., It is another object of the invention to provide a versatile method which is useful with both viable and non-viable skin.
.
It is still another object of the present invention to provide a simple, efficient, reproducible and economical method for enhancing transdermal permeation.
Summary of the Invention The present invention is a method using ultrasound for enhancing and controlling transdermal permeation of a molecule, including drugs, antigens, vitamins, inorganic and organic compounds, and various combinations of these substances, through the skin and into the circulatory system. The fre~uency and ~ ~ 2 ~ 6 -- intensity of ultrasonic energy which is applied, the media between the ultrasonic applicator and the skin, and the length of time of exposure are determined according to the type of skin and the substance to be diffused transdermally. Levels of the diffused molecules in the blood and urine measured over a period of time are initially used to determine under what conditions adequate transfer occurs.
The present invention relates to a method ` 10 for enhancing and controlling transdermal infusion of ~ molecules comprising:
- a) selecting the molecules to be infused;
b) applying said molecules in a medium with an absorption coefficient similar to that of water; and c) applying ultrasound to said molecules in said medium at a frequency of between 20 kHz and ; 10 MHz and an intensity of between 0 and 3 W/cm2 for a period of time selected to transdermally infuse said molecules at a controlled rate without damaging the skin.
In general, the frequency range of the ultrasound is between 20 kHz and 10 MHz, with intensities between 0 and 3 W/cm2. Intensity is decreased as the frequency is decreased to prevent damage to the skin. The preferred range of frequencies is between 0.5 MHz and 1.5 MHz and the preferred range of intensities is between 2 and 4 W/cm . Exposure is for between 1 and 10 minutes for most medical uses. The ultrasound may be pulsed or ' continuous. However, the frequency, intensity and ;~ time of exposure are interdependent as well as a j function of the molecule being diffused and the ... .
.
~ 2 ~ 6a -i nature of the skin at the site of exposure. One way ~ of determining the maximum limit of exposure is to ; measure skin temperature, decreasing or stopping the treatment when the temperature of the skin rises one S to two degrees Centrigrade.
In an alternate embodiment of the invention, ultrasonic energy is used to enhance -' passage of other molecules into and through non-living skin, for example, to increase the rate of diffusion of preservatives or dyes into animal hides or fine furs.
i .
-.~,i.
,~
';;i~
,:
., t ., '.~' .~.
'~i '.' Y ~
~. ,.~, Enhancement of both in vivo and in vitro transdermal transfer is shown by examples of the permeation of radiolabelled 3H-D-mannitol and 3H-inulin through the skin of rats and mice. A test solution of 5-20 microl. 3H-D-mannitol was applied to the back skin of hairless mice and to a shaven site on the upper back of the rats, followed by an aquasonic gel.
Radioactive excretion after topical application of 20 microl. of 3H-D-mannitol, followed immediately by ultrasound application at 1.5 2.0 W/cm2 for 2-3 minutes, showed that ultrasound treated rats had 20 times more radioactivity in the urine secreted during the first two hours than did the controls.
Brief Description of the Drawings -~` Fig. 1 is a cross-sectional view of human ~; skin.
~' Fig. 2 is a graph of the diffusion of 3H-D-Mannitol through the skin of rats with -4~
and without ~ ultrasound, and mice, with -C~O-and without 9 ultrasound.
~ Fig. 3 is a graph of the excretion of ; [3H]-D-Mannitol in the urine of rats after topical application of 20 microCi [3H]-D-Mannitol with -4~0~
or without ~ ultrasound.
Fig. 4 a-c are graphs of the percentage of 3H-drug excreted in the urine of rats over a period ` of ten hours after topical application of s~ (a) 20 microsCi [3H]-D-Mannitol, (b) 10 microCi [3H]-D-Mannitol, and (c) 50 microCi [3H]-Inulin, with ~ -4~ or without -gr~ ultrasound.
,'.~
., X
,, J J ~S ~
Fig. 5 is a graph of the percentage of 13H]-D-Mannitol excreted in the urine of hairless mice over a period of ten hours after topical application of 5 microCi with -~ >- and without ~ ~ ultrasound.
Detailed Description of the Invention The present invention is a method for enhancing the rate and efficacy of permeation of a drug into and through skin into the circulatory sy~tem which utilizes a limited exposure of the skin to ultrasound. The ultrasound alters the passage of the molecules through the stratum corneum, via inter-cellular, intra-cellular, and transappendageal penetration. The required length of time and frequency and intensity of ultrasound exposure are dependent on a number of factors including skin thickness and t~ resistance to permeation which varies from species to species, with age, injury or disease, and by location on the body.
Ultrasound is sound having a frequency greater than Z0 kHz. Ultrasound used for medical diagnostic purposes usually employs fre~uencies ranging from 1.6 to about 10 MHz. As :
disclosed here, frequencies of between 20 kHz and 10 MHz with intensities between 0 and 3 W/cm2, preferably between 2 and 4 W/cm2, are used to enhance transdermal transfer of molecules.
The preferred frequency range is between 0.5 MHz and 1.5 w/cm2.
Devices are available which emit both pulsed and continuous ultrasound. Exposures oE only a few minutes are usually sufficient since the response time to the ultrasoulld is very " , ~ 3 ~J ,i ~ ~t ~.
_9_ rapid. Care must be taken to avoid excessive exposure which might cause burning. The temperature of the skin is one indicator of overexposure. In the present invention, the temperature is held under 38C for human skin.
In the examples yiven below, rat and mouse skin is treated _ vivo with 1 to 2 W/cm2 ultrasound energy at a frequency of 870 kHz for one to three minutes. Rat and mouse skin is treated in vitro at lower frequencies, in the range of 75 kHz, for longer periods, up to two hours. Maximum effect of the ultrasound is achieved by applying it immediately after topical application. Little effect is noted if the ultrasound is applied more than ten hours after topical application of the drug.
The specific embodiment of the ultrasound device is not important. Probes, baths and boxes are all useful depending on ~ .
where the ultrasound is to be applied. A number of devices are commercially available. It is possible that an ultrasound applicator analogous to the high pressure devices commonly used for mass vaccinations could be developed for rapid, easy, repeated treatment of patients transdermally.
Ultrasound does not transmit well in air so a liquid media between the ultrasound applicator and the skin is preferred. Any type of aqueous or inorganic gel may be used, including one of the many com~ercially available products.
Preferably, the medium should have an absorption coefficient similar to that of water. Alternatively, the applicator may be 1~2~V ~ -lo-applied directly to a "patch" containing the molecules to be transdermally transferred, such as the drug patches presently in use for transdermal drug transfer without ultrasound. These patches generally consist of a protective cover, a matrix con-taining the drug, a support, and adhesive to hold the patch in place.
The advantage of using ultrasound is that the rate and efficiency of transfer is improved. Drugs which would simply not pass through the skin and into the circulatory system are forced throuyh the skin when ultrasound is applied. By controlling the frequency, intensity and time of exposure, the rate of transfer is controlled. Measurements taken over time of the blood or urine concentrations can be used to determine at what point the ultrasound conditions are correct.
In the preferred embodiment, ultrasound is used to enhance the passage of a compound such as a large molecular weight or polar molecule through the skin of a patient. Greater control and drug utilization is achieved by increasing the rate and directional control of the applied druy. The percentage of drug which quickly enters the bloodstream is increased accordingly and undesirable side eEEects avoided. The application of ultrasound allows transdermal infusion of drugs which would otherwise not be possible. The goal is to transder-mally infuse molecule~ into the bloo(3stream ~t an optimal rate.
In the transdermal devices or ~patches~ presently in use, even 1 3 ~
drugs with low molecular weights such as nitroglycerin take 30 minutes to enter the bloodstream. A hypertension drug such as Catapresan may take up to two days to fully enter the bloodstream. It is highly desirable to decrease the rate of entry of these drugs to a matter of a few minutes, approximately the time required for the drug to enter the bloodstream when given orally.
The safety and efficacy of the disclosed method was demonstrated by the following non-limiting example employing 3H-labelled Mannitol and Inulin.
`.
These compounds were selected since D-mannitol, a highly polar sugar alcohol, and inulin, a large molecular weight polysaccharide, m.w. 5200, are poor skin penetrants, thus enabling detection of minor permeation changes, and both D-mannitol and inulin are totally and rapidly excreted, permitting direct in vivo monitoring of the amount of the drug in the blood stream.
EXAMPLE 1: IN VITRO ENHANCEMENT OF SKIN PERMEABILITY
Skin permeability changes caused by ultrasound energy were determined by an in vitro diffusion procedure using double chamber cells. The diffusion cells were composed of two separate compartments (4.5 and 5.5 ml) designed to be clamped together across a 1.3 cm diameter opening in the side of each compartment. Magnetic stirring bars in each chamber were used for mixing. Animals were sacrified using CO2, and a piece of the dorsal skin ,~( . .
.
removed. ~kin specimens were held between the cells with a pressure clamp, the stratum corneum facing the donor solution.
The donor compartment contained 20 microCi D-3H-mannitol in a saturated solution of D-mannitol in buffered saline solution containing an 0.1 M phosphate at p~i 7.3. The receiver solution was buffered saline. The cells were placed in the center of a water-filled ul~rasonic bath, RAI Research Corporation Model 250, which generated an ultrasonic frequency of 75 kHz in a thermostated stainless steel tank of 3.5" x 3.5" x 2.5".
Permeability experiments were performed within the first two hours of switching in the ultrasound. 200 microliter samples were withdrawn from the receiver solution over time, and replaced with 200 microliters of buffered saline. The radioactivity of the withdrawn samples was measured by liquid scintillation counting. All experiments were conducted at room temperature, 22C. No ultrasound was applied on the controls.
Two hours of ultrasound irradiation at 75 kHz of cells contalning 3H-D-Mannitol solution diffusing through the skin of rats and mice in vitro caused a 50 to 80~ increase in drug per-meation, as shown in Fig. 2. The same effect was observe~ when the skin was irradiated for two hours before the drug was intro-duced into the donor cell.
Ultrasound irradiation did not damage mouse skin ~ermeability. I~owever, ~EM studies show a higher de~1ree o~
mechanical surface rupture ln the in vitro mouse skin irradiated ~s~ 13 -for 2 hours at 75 kHz and relatively high intensity, as compared to a control skin or to mouse skin irradiated in vivo for l min. at 870 kHz, l.5 W/cm2.
EXAMPLE 2: IN VIVO ENHANCEMENT OF SKIN PERMEABILITY
The effect of ultrasound energy on skin penetration of D-3H-mannitol and 3H-inulin in rats and mice in vivo was determined.
Sprague-Doweley (CD) male rats (weighing 200-250 g each) and hairless mice were used in this example. The conditions were chosen so as to minimize external skin damage. An ultrasonic therapy unit, Burdick UT420A, approved for use in the treatment of human and animal tissue to facilitate healing through a combination of mechanical and thermal effects, was used for the in vivo studies.
Test solutions of 5 to 20 microliter D-3H-mannitol were applied to a shaven site in the upper back of the rats, followed by an aquasonic gel.
Surface changes in skin from both in vivo and ln vitro experiments were investigated by electromicroscopy technique. For scanning electron microscopy (SEM) examination, pieces of dorsal skin from the mice and rats were fixed with 2%
glutaraldehyde, followed by 1% osmium tetroxide, dehydrated in a series of ascending alcohol concentrations, followed by critical point drying and examined with the electron microscope.
Measurement of the amount of drug excreted in the urine was determinative of the rate of permeation in in vivo studies.
~' , J ~
Urine was collected via a catheter inserted into the bladder.
The incision was stitched closed and the rat put in a restrainer.
Test solutions of 1~ microl. 3H-D-mannitol and 12.5-50 microl.
3H-inulin were applied to the skin, followed by ultrasound application. Urine was collected every lS-3~ minutes for the first 2 hours and at several time points afterwards. Volume and radioactivity of each urine sample was measured.
Urine samples of ultrasound treated and control rats were compared by thin layer chromatography on silica plates developed in t-butanol:pyridine:water ~6:4:3) visualized by phosphomolybdic acid reagent. The develped silica gel plate was cut into several sections according to the distance migrated by the spots relative to each other ~R) and the pieces placed in scintillation vials. One milliliter of distilled water was added to each vial to dissolve the drùg. 10 ml of Aquasol~ ~New England Nuclear, Boston, MA) scintillation liquid was added, and the radioactlvity measured.
Fig. 3 compares excretion of 3H-D-mannitol after topical application of 20 microliter radiolabeled 3H-D-mannitol, ,~ followed immediately by ultrasound treatment at 1.5-2.0 W/cm2 for 2-3 minutes, with excretion by control rats (no ultrasound). The -~ ultrasound treated rats had 20 times more radioactivity in their urine during the irst two hours than did the control rats. The effect Oe the ultrasound decreased with time. After 1~ hours the ~ radioactivity in the urine of the two grotl~s W~3 ':
~' ~ ~ 2. ~ Q.
indistinguishable. The difference in release rate of 3H-~-mannitol was observed only if the ultrasound treatment was applied immediately after drug application. When the rats were treated with ultrasound, lO or more hours after drug application, no change in the release rate was observ~d.
.
Mannitol is totally and rapidly eliminated from the body and therefore appears completely in the urine. The effect of ultrasound on the permeating molecules as evaluated by thin layer chromatography indicated no decomposition of the mannitol by the ultrasonic energy.
Fig. 4 compares the percentage of excreted 13H] at a specific time interval to total amount of radioactivity excreted over lO hours following topical application of both 3H-D-mannitol and 3H-inulin in rats. This was used as a measure o the relative druy penetration. In the ultrasound treated rats the percenta~es of ~3HI excreted during the first two hours were 20 to 30% for 3H-D-mannitol and 50~ for 3H-inulin as compared to 2-5~ for 3H-D-mannitol and lO~ for 3H-inulin in the respective controls. As shown by Table I, the ratio of relative drug permeation, ~, is defined as:
PUs(t) R(t) =
PCt(t) where Pu~ is the percentage of 13HI in urine of ultrasound treated rats at a time, t, divided by the total amount of 13H
`:
e-~ ?~ J `~ ~, excreted in the urine over 10 hours. Pct is the percentage of[3Hl in the urine of untreated rats at a time, t, divided by the total amount of l3Hl excreted by the rats over a period of ten hours. As can be seen from Table I, skin permeation for both drugs was 6 to 2U fold greater in ultrasound treated rats during the Eirst 2 hours ~han that oE the corresponding control group.
`~`
,:
''s .:
1 ~3 h ~ 17-.
Table I
Ratio of relative drug permeation in rats time D-3H-mannitol 3~-inulin thours) 20 mCi lO mCi 50 mCi 2 l9 l9 6 2.5 1.5 1.5 Figure 5 shows the relative D-mannitol permeation in mice after the application of 5 microl. 3H-D-mannitol followed immediately by ultrasound treatment at l-l.5 w/cm2 for l min.
The results are expressed as the percentage of [3H1 excreted at a specified time divided by the total [3HI excreted over ten hours.
There was no change in the yercentage of excreted radioactivity when the ultrasound treatment was applied lO hours after drug application.
;~ These examples demonstrate that the transdermal permeation of 3H-D-mannitol and 3H-inulin in rats is increased 6-20 fold within the first two hours of ultrasound treatment.
This increase was o~served only duriny the initial phase of the transdermal permeatlon, beEore establ1shment oE a steady state.
The fact that the ultrasound energy shortened the lag time for transdermal permeation of D-mannitol and inulin in rats, and did not change the drug release rate during the steady-state phase, suggests that the ultrasound treatment enhanced the diffusion of the administered drugs through an alternative pathway such as the hair follicles in the rat's skin, rather than diffusion through the bulk of the stratum coreum.
Intensities of less than 5 W/cm2 of ultrasound at a frequency of 1 MHz do not result in a significant temperature rise nor have any destructive effect on viable mouse or rat skin. Skin temperature did not increase more than 1C when ultrasound energy was applied for less than 3 minutes to rats at less than 3 W/cm2 or 1 minute to mice at 1.5 W/cm2. Longer treatment sometimes caused skin burns.
., In summary, the examples using skin from two species, both in vivo and in vitro, demonstrate that ultrasound is an effective means of enhancing the passage of molecules through skin and into the circulatory system. Frequencies, power and time of application can be optimized to suit the individual situation, both with respect to the type of skin and the molecules to be diffused.
Although this invention has been described with reference to specific embodiments, it is understood that modifications and variations of the method for using ultrasound energy to enhance passage of molecules into and through skin may ' X
.
~ ;j2 ~ ~3 ,:~
occur to those skilled in the art. It is intended that all such modifications and variations be included witllin the scope of the appended claims.
~"
1:
's~
f
ULTRASOUND ENHANCEMENT OF TRANSDERMAL DRUG DELIVERY
~acl;~round o the Invention -This invention is generally in the field of drug delivery and more particularly in the area of ultrasound enhanced and controlled transdermal drug delivery.
Drugs are routinely administered either orally or by injection. The ef~ectiveness of most drugs relies on achieving a certain concentration in the bloodstream. Although some drugs have inherent side effects whlch cannot be eliminated in any dosaye form, many drugs exhibit undesirable behaviors that are specifically related to a particular route of administration.
For example, drugs may be degraded in the GI tract by the low gastric pH, local enzymes or interaction with food or drink within the stomach. The drug or disease itself may forestall or compromise drug absorption because of vomiting or diarrhea. If a drug entity survives its trip through the GI tract, it may face rapid metabolism to pharmacologically inactive forms by the liver, the first-pass effect. Sometimes the drug itself has inherent undesirable attributes such as a short half-life, high potency or a narrow therapeutic blood level range.
Recently, eforts aimed at eliminating some of the problems of traditional dosage forms involve transdermal delivery of the drugs. Topical application has been used for a very long ,, ~ 2 -time, mostly in the treatment of localized skin diseases. Local treatment, however, only requires that the drug permeate the outer layers of the skin to treat the diseased state, with little or no systemic accumulation. Transdermal delivery systems are specifically designed to obtain systemic blood levels. Transdermal permeation or percutaneous absorption can be defined as the passage of a substance, such as a drug, from the outside of the skin through its various layers into the bloodstream.
The transport of drugs through the skin is complex since many factors influence their permeation. These include the skin structure and its properties, the penetrating molecule and its physical-chemical relationship to the skin and the delivery matrix, and the combination of the skin, the penetrant, and the delivery system as a whole.
Topical application of drugs has focused much attention on skin permeability properties. Many reports have described efforts to change skin permeability using chemical enhancers, molecules which enter the stratum corneum and decrease its resistance to drug penetration, or by external means such as iontophoresis~ Chemical agents such as dimethylsulfoxide (DMSO), or 1-dodecylazacycloheptan-2-one (Azone), tend to enhance the penetration of drugs that are incorporated within them. However, in all of these systems, with the exception of iontophoresis, there is no way of externally controlling the rate of drug release.
U.S. Patent No. 4,309,989 to Fahim discloses the topical application of a medication using ultrasound with a coupling agent such as oil.
Ultrasound at a frequency of at least 1000 kHz and a power of one to three W/cm2 was used to cause selective localized intercellular concentration of a zinc containing compound for the treatment of herpes simplex virus. An important limitation of the disclosed method is that it applies only to topical application and intracellular localization of the drug.
As shown in Fig. 1, the skin is a complex structure. There are at least four distinct layers of tissue: the non-viable epidermis (stratum corneum), the viable epidermis, the viable dermis (corium), and the subcutaneous connective tissue thypodermis).
Located within these layers are the skin's circulatory system, the arterial plexus, and appendages, including hair follicles, sebaceous glands and sweat glands. The circulatory system lies in the dermis and tissues below the dermis. Diffusion mechanisms provide for the exchange of nutrients between the epidermis and the blood. The capillaries do not actually enter the epidermal structure but come within 150 to 200 microns of the outer surface of the skin.
As shown in Fig. 1, permeation of the skin can occur by (a) transcellular penetration, through the stratum corneum;
(b) intercellular penetration, through the stratum corneum; and (c) transappendageal penetration, especially including the sebaceous pathway of the pilosebaceous apparatus and the aqueous pathway of the salty sweat glands. The first two mechanisms require further diffusion through the rest of the epidermis and dermis. The third mechanism allows diffusional leakage into the epidermis and direct permeation into the dermis.
X
:
:
Transdermal delivery of drugs has attributes that make it far superior to other modes of systemic drug ~dministration. Despite these advantages, relatively few drugs are deliverable transdermally. The majority of drugs will not penetrate the skin at rates sufficiently high for therapeutic efficacy.
In vitro steady state fluxes of a drug through the skin have ranged as low as .00013 microg/cm2 hr digitoxin to 300 microg/cm2 hr for ephadrine. Several factors on the nature of skin must be considered in determining the degree of transdermal permeation. For example, the type of skin which the substance is to pass through varies from species to species, varies according to age, with the skin of an infant having a greater permeability than that of an older adult, varies according to local composition, thickness and density, varies as a function of injury or exposure to agents such as organic solvents or surfactants, and varies as a function of some diseases such as psoriasis or abrasion. In order to allow clinically useful transdermal application of drugs, some way to enhance and control their rates of penetration must be found.
It is therefore an object of the invention to provide a method for enhancing an controlling permeation of a molecule through the skin and into the circulatory system.
.
1 ", ~ `~
It is a further object of the invention to provide a method for enhancing permeation which operates externally to the skin and does not harm either the skin or the molecules being in~used.
It is still another object of the invention to provide an improved method for transdermal delivery of drugs where the primary goal is to achieve a suitable therapeutic blood level.
It is a further object of the present invention to provide an improved method for transdermal delivery of a drug which is useful with a variety of molecules, including molecules soluble in an aqueous, inorganic or lipid solution.
., It is another object of the invention to provide a versatile method which is useful with both viable and non-viable skin.
.
It is still another object of the present invention to provide a simple, efficient, reproducible and economical method for enhancing transdermal permeation.
Summary of the Invention The present invention is a method using ultrasound for enhancing and controlling transdermal permeation of a molecule, including drugs, antigens, vitamins, inorganic and organic compounds, and various combinations of these substances, through the skin and into the circulatory system. The fre~uency and ~ ~ 2 ~ 6 -- intensity of ultrasonic energy which is applied, the media between the ultrasonic applicator and the skin, and the length of time of exposure are determined according to the type of skin and the substance to be diffused transdermally. Levels of the diffused molecules in the blood and urine measured over a period of time are initially used to determine under what conditions adequate transfer occurs.
The present invention relates to a method ` 10 for enhancing and controlling transdermal infusion of ~ molecules comprising:
- a) selecting the molecules to be infused;
b) applying said molecules in a medium with an absorption coefficient similar to that of water; and c) applying ultrasound to said molecules in said medium at a frequency of between 20 kHz and ; 10 MHz and an intensity of between 0 and 3 W/cm2 for a period of time selected to transdermally infuse said molecules at a controlled rate without damaging the skin.
In general, the frequency range of the ultrasound is between 20 kHz and 10 MHz, with intensities between 0 and 3 W/cm2. Intensity is decreased as the frequency is decreased to prevent damage to the skin. The preferred range of frequencies is between 0.5 MHz and 1.5 MHz and the preferred range of intensities is between 2 and 4 W/cm . Exposure is for between 1 and 10 minutes for most medical uses. The ultrasound may be pulsed or ' continuous. However, the frequency, intensity and ;~ time of exposure are interdependent as well as a j function of the molecule being diffused and the ... .
.
~ 2 ~ 6a -i nature of the skin at the site of exposure. One way ~ of determining the maximum limit of exposure is to ; measure skin temperature, decreasing or stopping the treatment when the temperature of the skin rises one S to two degrees Centrigrade.
In an alternate embodiment of the invention, ultrasonic energy is used to enhance -' passage of other molecules into and through non-living skin, for example, to increase the rate of diffusion of preservatives or dyes into animal hides or fine furs.
i .
-.~,i.
,~
';;i~
,:
., t ., '.~' .~.
'~i '.' Y ~
~. ,.~, Enhancement of both in vivo and in vitro transdermal transfer is shown by examples of the permeation of radiolabelled 3H-D-mannitol and 3H-inulin through the skin of rats and mice. A test solution of 5-20 microl. 3H-D-mannitol was applied to the back skin of hairless mice and to a shaven site on the upper back of the rats, followed by an aquasonic gel.
Radioactive excretion after topical application of 20 microl. of 3H-D-mannitol, followed immediately by ultrasound application at 1.5 2.0 W/cm2 for 2-3 minutes, showed that ultrasound treated rats had 20 times more radioactivity in the urine secreted during the first two hours than did the controls.
Brief Description of the Drawings -~` Fig. 1 is a cross-sectional view of human ~; skin.
~' Fig. 2 is a graph of the diffusion of 3H-D-Mannitol through the skin of rats with -4~
and without ~ ultrasound, and mice, with -C~O-and without 9 ultrasound.
~ Fig. 3 is a graph of the excretion of ; [3H]-D-Mannitol in the urine of rats after topical application of 20 microCi [3H]-D-Mannitol with -4~0~
or without ~ ultrasound.
Fig. 4 a-c are graphs of the percentage of 3H-drug excreted in the urine of rats over a period ` of ten hours after topical application of s~ (a) 20 microsCi [3H]-D-Mannitol, (b) 10 microCi [3H]-D-Mannitol, and (c) 50 microCi [3H]-Inulin, with ~ -4~ or without -gr~ ultrasound.
,'.~
., X
,, J J ~S ~
Fig. 5 is a graph of the percentage of 13H]-D-Mannitol excreted in the urine of hairless mice over a period of ten hours after topical application of 5 microCi with -~ >- and without ~ ~ ultrasound.
Detailed Description of the Invention The present invention is a method for enhancing the rate and efficacy of permeation of a drug into and through skin into the circulatory sy~tem which utilizes a limited exposure of the skin to ultrasound. The ultrasound alters the passage of the molecules through the stratum corneum, via inter-cellular, intra-cellular, and transappendageal penetration. The required length of time and frequency and intensity of ultrasound exposure are dependent on a number of factors including skin thickness and t~ resistance to permeation which varies from species to species, with age, injury or disease, and by location on the body.
Ultrasound is sound having a frequency greater than Z0 kHz. Ultrasound used for medical diagnostic purposes usually employs fre~uencies ranging from 1.6 to about 10 MHz. As :
disclosed here, frequencies of between 20 kHz and 10 MHz with intensities between 0 and 3 W/cm2, preferably between 2 and 4 W/cm2, are used to enhance transdermal transfer of molecules.
The preferred frequency range is between 0.5 MHz and 1.5 w/cm2.
Devices are available which emit both pulsed and continuous ultrasound. Exposures oE only a few minutes are usually sufficient since the response time to the ultrasoulld is very " , ~ 3 ~J ,i ~ ~t ~.
_9_ rapid. Care must be taken to avoid excessive exposure which might cause burning. The temperature of the skin is one indicator of overexposure. In the present invention, the temperature is held under 38C for human skin.
In the examples yiven below, rat and mouse skin is treated _ vivo with 1 to 2 W/cm2 ultrasound energy at a frequency of 870 kHz for one to three minutes. Rat and mouse skin is treated in vitro at lower frequencies, in the range of 75 kHz, for longer periods, up to two hours. Maximum effect of the ultrasound is achieved by applying it immediately after topical application. Little effect is noted if the ultrasound is applied more than ten hours after topical application of the drug.
The specific embodiment of the ultrasound device is not important. Probes, baths and boxes are all useful depending on ~ .
where the ultrasound is to be applied. A number of devices are commercially available. It is possible that an ultrasound applicator analogous to the high pressure devices commonly used for mass vaccinations could be developed for rapid, easy, repeated treatment of patients transdermally.
Ultrasound does not transmit well in air so a liquid media between the ultrasound applicator and the skin is preferred. Any type of aqueous or inorganic gel may be used, including one of the many com~ercially available products.
Preferably, the medium should have an absorption coefficient similar to that of water. Alternatively, the applicator may be 1~2~V ~ -lo-applied directly to a "patch" containing the molecules to be transdermally transferred, such as the drug patches presently in use for transdermal drug transfer without ultrasound. These patches generally consist of a protective cover, a matrix con-taining the drug, a support, and adhesive to hold the patch in place.
The advantage of using ultrasound is that the rate and efficiency of transfer is improved. Drugs which would simply not pass through the skin and into the circulatory system are forced throuyh the skin when ultrasound is applied. By controlling the frequency, intensity and time of exposure, the rate of transfer is controlled. Measurements taken over time of the blood or urine concentrations can be used to determine at what point the ultrasound conditions are correct.
In the preferred embodiment, ultrasound is used to enhance the passage of a compound such as a large molecular weight or polar molecule through the skin of a patient. Greater control and drug utilization is achieved by increasing the rate and directional control of the applied druy. The percentage of drug which quickly enters the bloodstream is increased accordingly and undesirable side eEEects avoided. The application of ultrasound allows transdermal infusion of drugs which would otherwise not be possible. The goal is to transder-mally infuse molecule~ into the bloo(3stream ~t an optimal rate.
In the transdermal devices or ~patches~ presently in use, even 1 3 ~
drugs with low molecular weights such as nitroglycerin take 30 minutes to enter the bloodstream. A hypertension drug such as Catapresan may take up to two days to fully enter the bloodstream. It is highly desirable to decrease the rate of entry of these drugs to a matter of a few minutes, approximately the time required for the drug to enter the bloodstream when given orally.
The safety and efficacy of the disclosed method was demonstrated by the following non-limiting example employing 3H-labelled Mannitol and Inulin.
`.
These compounds were selected since D-mannitol, a highly polar sugar alcohol, and inulin, a large molecular weight polysaccharide, m.w. 5200, are poor skin penetrants, thus enabling detection of minor permeation changes, and both D-mannitol and inulin are totally and rapidly excreted, permitting direct in vivo monitoring of the amount of the drug in the blood stream.
EXAMPLE 1: IN VITRO ENHANCEMENT OF SKIN PERMEABILITY
Skin permeability changes caused by ultrasound energy were determined by an in vitro diffusion procedure using double chamber cells. The diffusion cells were composed of two separate compartments (4.5 and 5.5 ml) designed to be clamped together across a 1.3 cm diameter opening in the side of each compartment. Magnetic stirring bars in each chamber were used for mixing. Animals were sacrified using CO2, and a piece of the dorsal skin ,~( . .
.
removed. ~kin specimens were held between the cells with a pressure clamp, the stratum corneum facing the donor solution.
The donor compartment contained 20 microCi D-3H-mannitol in a saturated solution of D-mannitol in buffered saline solution containing an 0.1 M phosphate at p~i 7.3. The receiver solution was buffered saline. The cells were placed in the center of a water-filled ul~rasonic bath, RAI Research Corporation Model 250, which generated an ultrasonic frequency of 75 kHz in a thermostated stainless steel tank of 3.5" x 3.5" x 2.5".
Permeability experiments were performed within the first two hours of switching in the ultrasound. 200 microliter samples were withdrawn from the receiver solution over time, and replaced with 200 microliters of buffered saline. The radioactivity of the withdrawn samples was measured by liquid scintillation counting. All experiments were conducted at room temperature, 22C. No ultrasound was applied on the controls.
Two hours of ultrasound irradiation at 75 kHz of cells contalning 3H-D-Mannitol solution diffusing through the skin of rats and mice in vitro caused a 50 to 80~ increase in drug per-meation, as shown in Fig. 2. The same effect was observe~ when the skin was irradiated for two hours before the drug was intro-duced into the donor cell.
Ultrasound irradiation did not damage mouse skin ~ermeability. I~owever, ~EM studies show a higher de~1ree o~
mechanical surface rupture ln the in vitro mouse skin irradiated ~s~ 13 -for 2 hours at 75 kHz and relatively high intensity, as compared to a control skin or to mouse skin irradiated in vivo for l min. at 870 kHz, l.5 W/cm2.
EXAMPLE 2: IN VIVO ENHANCEMENT OF SKIN PERMEABILITY
The effect of ultrasound energy on skin penetration of D-3H-mannitol and 3H-inulin in rats and mice in vivo was determined.
Sprague-Doweley (CD) male rats (weighing 200-250 g each) and hairless mice were used in this example. The conditions were chosen so as to minimize external skin damage. An ultrasonic therapy unit, Burdick UT420A, approved for use in the treatment of human and animal tissue to facilitate healing through a combination of mechanical and thermal effects, was used for the in vivo studies.
Test solutions of 5 to 20 microliter D-3H-mannitol were applied to a shaven site in the upper back of the rats, followed by an aquasonic gel.
Surface changes in skin from both in vivo and ln vitro experiments were investigated by electromicroscopy technique. For scanning electron microscopy (SEM) examination, pieces of dorsal skin from the mice and rats were fixed with 2%
glutaraldehyde, followed by 1% osmium tetroxide, dehydrated in a series of ascending alcohol concentrations, followed by critical point drying and examined with the electron microscope.
Measurement of the amount of drug excreted in the urine was determinative of the rate of permeation in in vivo studies.
~' , J ~
Urine was collected via a catheter inserted into the bladder.
The incision was stitched closed and the rat put in a restrainer.
Test solutions of 1~ microl. 3H-D-mannitol and 12.5-50 microl.
3H-inulin were applied to the skin, followed by ultrasound application. Urine was collected every lS-3~ minutes for the first 2 hours and at several time points afterwards. Volume and radioactivity of each urine sample was measured.
Urine samples of ultrasound treated and control rats were compared by thin layer chromatography on silica plates developed in t-butanol:pyridine:water ~6:4:3) visualized by phosphomolybdic acid reagent. The develped silica gel plate was cut into several sections according to the distance migrated by the spots relative to each other ~R) and the pieces placed in scintillation vials. One milliliter of distilled water was added to each vial to dissolve the drùg. 10 ml of Aquasol~ ~New England Nuclear, Boston, MA) scintillation liquid was added, and the radioactlvity measured.
Fig. 3 compares excretion of 3H-D-mannitol after topical application of 20 microliter radiolabeled 3H-D-mannitol, ,~ followed immediately by ultrasound treatment at 1.5-2.0 W/cm2 for 2-3 minutes, with excretion by control rats (no ultrasound). The -~ ultrasound treated rats had 20 times more radioactivity in their urine during the irst two hours than did the control rats. The effect Oe the ultrasound decreased with time. After 1~ hours the ~ radioactivity in the urine of the two grotl~s W~3 ':
~' ~ ~ 2. ~ Q.
indistinguishable. The difference in release rate of 3H-~-mannitol was observed only if the ultrasound treatment was applied immediately after drug application. When the rats were treated with ultrasound, lO or more hours after drug application, no change in the release rate was observ~d.
.
Mannitol is totally and rapidly eliminated from the body and therefore appears completely in the urine. The effect of ultrasound on the permeating molecules as evaluated by thin layer chromatography indicated no decomposition of the mannitol by the ultrasonic energy.
Fig. 4 compares the percentage of excreted 13H] at a specific time interval to total amount of radioactivity excreted over lO hours following topical application of both 3H-D-mannitol and 3H-inulin in rats. This was used as a measure o the relative druy penetration. In the ultrasound treated rats the percenta~es of ~3HI excreted during the first two hours were 20 to 30% for 3H-D-mannitol and 50~ for 3H-inulin as compared to 2-5~ for 3H-D-mannitol and lO~ for 3H-inulin in the respective controls. As shown by Table I, the ratio of relative drug permeation, ~, is defined as:
PUs(t) R(t) =
PCt(t) where Pu~ is the percentage of 13HI in urine of ultrasound treated rats at a time, t, divided by the total amount of 13H
`:
e-~ ?~ J `~ ~, excreted in the urine over 10 hours. Pct is the percentage of[3Hl in the urine of untreated rats at a time, t, divided by the total amount of l3Hl excreted by the rats over a period of ten hours. As can be seen from Table I, skin permeation for both drugs was 6 to 2U fold greater in ultrasound treated rats during the Eirst 2 hours ~han that oE the corresponding control group.
`~`
,:
''s .:
1 ~3 h ~ 17-.
Table I
Ratio of relative drug permeation in rats time D-3H-mannitol 3~-inulin thours) 20 mCi lO mCi 50 mCi 2 l9 l9 6 2.5 1.5 1.5 Figure 5 shows the relative D-mannitol permeation in mice after the application of 5 microl. 3H-D-mannitol followed immediately by ultrasound treatment at l-l.5 w/cm2 for l min.
The results are expressed as the percentage of [3H1 excreted at a specified time divided by the total [3HI excreted over ten hours.
There was no change in the yercentage of excreted radioactivity when the ultrasound treatment was applied lO hours after drug application.
;~ These examples demonstrate that the transdermal permeation of 3H-D-mannitol and 3H-inulin in rats is increased 6-20 fold within the first two hours of ultrasound treatment.
This increase was o~served only duriny the initial phase of the transdermal permeatlon, beEore establ1shment oE a steady state.
The fact that the ultrasound energy shortened the lag time for transdermal permeation of D-mannitol and inulin in rats, and did not change the drug release rate during the steady-state phase, suggests that the ultrasound treatment enhanced the diffusion of the administered drugs through an alternative pathway such as the hair follicles in the rat's skin, rather than diffusion through the bulk of the stratum coreum.
Intensities of less than 5 W/cm2 of ultrasound at a frequency of 1 MHz do not result in a significant temperature rise nor have any destructive effect on viable mouse or rat skin. Skin temperature did not increase more than 1C when ultrasound energy was applied for less than 3 minutes to rats at less than 3 W/cm2 or 1 minute to mice at 1.5 W/cm2. Longer treatment sometimes caused skin burns.
., In summary, the examples using skin from two species, both in vivo and in vitro, demonstrate that ultrasound is an effective means of enhancing the passage of molecules through skin and into the circulatory system. Frequencies, power and time of application can be optimized to suit the individual situation, both with respect to the type of skin and the molecules to be diffused.
Although this invention has been described with reference to specific embodiments, it is understood that modifications and variations of the method for using ultrasound energy to enhance passage of molecules into and through skin may ' X
.
~ ;j2 ~ ~3 ,:~
occur to those skilled in the art. It is intended that all such modifications and variations be included witllin the scope of the appended claims.
~"
1:
's~
f
Claims (13)
1. Use of molecules to be infused, said molecules being presented in a medium with an absorption coefficient similar to that of water, ultrasound being applied to said molecules in said medium at a frequency of between 20 kHz and 10 MHz and an intensity of between 0 and 3 W/cm2 for enhancing and controlling transdermal infusion of said molecules.
2. Use of claim 1, wherein the ultrasound frequency is applied at between 0.5 MHz and 1.5 MHz and an intensity of between 2 and 4 W/cm2.
3. Use of claim 1, wherein the ultrasound is applied for less than 10 minutes.
4. Use of claim 1, wherein the medium is an aqueous gel.
5. Use of claim 1, wherein the medium is a transdermal drug patch comprising a support, adhesive, a drug-containing matrix and a protective covering.
6. Use of claim 1, wherein the ultrasound is applied continuously.
7. Use of claim 1, wherein the ultrasound is pulsed.
8. Use of claim 1, wherein said molecule is selected from the group of molecules consisting of proteins, drugs, antigens, vitamins, inorganic compounds, organic compounds, and combinations thereof, wherein said molecule has a biological effect when infused into the circulatory system.
9. Use of claim 8, wherein the ultrasound is applied at a frequency and intensity over a period of time which does not cause an increase in skin temperature of more than 2°C.
10. Use of claim 1, which is adjusted in accordance with measurements of the concentration of said molecules in body fluid of a patient under treatment.
11. Use of claim 10, which is adjusted in accordance with measurements of the concentrations of said molecule over time and in dependence of the rate of transdermal transfer for said molecules at specific frequencies, intensities and times of ultrasound application.
12. Use of claim 11, characterized by altering the frequency, intensity and time of ultrasound application so as to optimize the rate of transdermal transfer of said molecule.
13. Use of claim 1, wherein said molecule is selected from the group of molecules comprising dyes, preservatives, and other molecules for the treatment of leather and furs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/883,111 US4767402A (en) | 1986-07-08 | 1986-07-08 | Ultrasound enhancement of transdermal drug delivery |
| US883,111 | 1986-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1324051C true CA1324051C (en) | 1993-11-09 |
Family
ID=25382010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000541496A Expired - Lifetime CA1324051C (en) | 1986-07-08 | 1987-07-07 | Ultrasound enhancement of transdermal drug delivery |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4767402A (en) |
| EP (1) | EP0275284A1 (en) |
| JP (1) | JP2710281B2 (en) |
| CA (1) | CA1324051C (en) |
| WO (1) | WO1988000001A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8224414B2 (en) | 2004-10-28 | 2012-07-17 | Echo Therapeutics, Inc. | System and method for analyte sampling and analysis with hydrogel |
| US8287483B2 (en) | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
| US8812071B2 (en) | 2007-03-07 | 2014-08-19 | Echo Therapeutics, Inc. | Transdermal analyte monitoring systems and methods for analyte detection |
| US8870810B2 (en) | 1998-12-18 | 2014-10-28 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
Families Citing this family (251)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956032B1 (en) | 1986-04-18 | 2005-10-18 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| JPS63135179A (en) * | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
| US5332577A (en) * | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
| US5241925A (en) * | 1988-12-27 | 1993-09-07 | Dermamed | Apparatus and techniques for administering veterinary medicaments |
| US4979938A (en) * | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
| DE3915636C1 (en) | 1989-05-12 | 1990-04-26 | Sass, Wolfgang, Dr. | |
| US5141131A (en) * | 1989-06-30 | 1992-08-25 | Dowelanco | Method and apparatus for the acceleration of a propellable matter |
| US5324521A (en) * | 1989-12-18 | 1994-06-28 | Dermamed | Systems for transdermal administration of medicaments |
| US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
| US5115805A (en) * | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
| US5231975A (en) * | 1990-02-23 | 1993-08-03 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
| US5236413B1 (en) * | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
| US5147291A (en) * | 1990-06-11 | 1992-09-15 | Cukier A David | Sound transmission apparatus for uniformly administering chemical composition through the skin |
| EP0533816B1 (en) * | 1990-06-15 | 1995-06-14 | Cortrak Medical, Inc. | Drug delivery apparatus |
| US5498238A (en) * | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
| US5076208A (en) * | 1990-09-14 | 1991-12-31 | Massachusetts Institute Of Technology | Ultrasound-mediated administration of compounds into aquatic animals |
| US5254081A (en) * | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
| US5458568A (en) * | 1991-05-24 | 1995-10-17 | Cortrak Medical, Inc. | Porous balloon for selective dilatation and drug delivery |
| US5171215A (en) * | 1991-08-22 | 1992-12-15 | Flanagan Dennis F | Endermic method and apparatus |
| US5421816A (en) * | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
| US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
| US5267985A (en) * | 1993-02-11 | 1993-12-07 | Trancell, Inc. | Drug delivery by multiple frequency phonophoresis |
| US5667487A (en) * | 1993-04-07 | 1997-09-16 | Henley; Julian L. | Ionosonic drug delivery apparatus |
| JP3415203B2 (en) * | 1993-07-12 | 2003-06-09 | 立花 克郎 | Ultrasound generator for therapy |
| US5415629A (en) * | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
| US5458140A (en) * | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
| US5814599A (en) * | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
| US5445611A (en) * | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
| US6176842B1 (en) | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
| IL114162A (en) | 1995-06-15 | 1999-03-12 | Ostrow Alvin Stewart | Submersive therapy apparatus |
| US6041253A (en) * | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
| EP0781150B1 (en) * | 1995-07-25 | 2002-11-06 | Massachusetts Institute Of Technology | Enhanced transdermal transport using ultrasound |
| US5947921A (en) * | 1995-12-18 | 1999-09-07 | Massachusetts Institute Of Technology | Chemical and physical enhancers and ultrasound for transdermal drug delivery |
| US6002961A (en) * | 1995-07-25 | 1999-12-14 | Massachusetts Institute Of Technology | Transdermal protein delivery using low-frequency sonophoresis |
| US5833647A (en) * | 1995-10-10 | 1998-11-10 | The Penn State Research Foundation | Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery |
| WO1997017933A1 (en) * | 1995-11-15 | 1997-05-22 | Aeropag Usa, Inc. | Method of spraying a surface using ultrasonic radiation |
| US6009343A (en) * | 1996-02-23 | 1999-12-28 | Abbott Laboratories | Enhanced transdermal transport of fluid using vacuum |
| US5785688A (en) * | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
| JP2002515786A (en) * | 1996-06-28 | 2002-05-28 | ソントラ メディカル，エル．ピー． | Ultrasound enhancement of transdermal delivery |
| US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
| US5913833A (en) * | 1997-02-07 | 1999-06-22 | Abbott Laboratories | Method and apparatus for obtaining biological fluids |
| US6582392B1 (en) * | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
| US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
| US5980934A (en) * | 1997-05-19 | 1999-11-09 | Motorola, Inc. | Transdermal delivery apparatus |
| KR100471542B1 (en) * | 1997-06-21 | 2005-06-10 | 삼성토탈 주식회사 | Polypropylene Resin Composition |
| WO1999010031A1 (en) * | 1997-08-27 | 1999-03-04 | Farrens Frank L | Device for injecting material beneath the skin of a human or animal |
| US6013513A (en) * | 1997-10-30 | 2000-01-11 | Motorola, Inc. | Molecular detection apparatus |
| WO1999034857A1 (en) | 1998-01-08 | 1999-07-15 | Sontra Medical, Inc. | Sonophoretic enhanced transdermal transport |
| US20060015058A1 (en) * | 1998-01-08 | 2006-01-19 | Kellogg Scott C | Agents and methods for enhancement of transdermal transport |
| US7066884B2 (en) | 1998-01-08 | 2006-06-27 | Sontra Medical, Inc. | System, method, and device for non-invasive body fluid sampling and analysis |
| US20020055702A1 (en) * | 1998-02-10 | 2002-05-09 | Anthony Atala | Ultrasound-mediated drug delivery |
| US6398753B2 (en) | 1998-04-03 | 2002-06-04 | Mcdaniel David H. | Ultrasound enhancement of percutaneous drug absorption |
| US6030374A (en) * | 1998-05-29 | 2000-02-29 | Mcdaniel; David H. | Ultrasound enhancement of percutaneous drug absorption |
| US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
| US7004933B2 (en) | 1998-05-29 | 2006-02-28 | Light Bioscience L.L.C. | Ultrasound enhancement of percutaneous drug absorption |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| IL140493A0 (en) | 1998-06-24 | 2002-02-10 | Transderm Diagnostics Inc | Non-invasive transdermal detection of analytes |
| US6532386B2 (en) | 1998-08-31 | 2003-03-11 | Johnson & Johnson Consumer Companies, Inc. | Electrotransort device comprising blades |
| US6148231A (en) * | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
| US7229621B2 (en) * | 1998-10-20 | 2007-06-12 | Torrey Pines Institute For Molecular Studies | Method to enhance the immunogenicity of an antigen |
| DE19850517B4 (en) * | 1998-11-03 | 2004-02-12 | Lts Lohmann Therapie-Systeme Ag | Use of an active substance-containing transdermal therapeutic system in a combined treatment with and without ultrasound |
| US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
| US6936044B2 (en) * | 1998-11-30 | 2005-08-30 | Light Bioscience, Llc | Method and apparatus for the stimulation of hair growth |
| US6887260B1 (en) * | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US6663659B2 (en) | 2000-01-13 | 2003-12-16 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
| US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
| US6676655B2 (en) | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
| US20060212025A1 (en) * | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US6231528B1 (en) * | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
| US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
| US7127285B2 (en) | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
| US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
| ATE290902T1 (en) | 1999-04-16 | 2005-04-15 | Johnson & Johnson Consumer | DEVICE FOR IONTOPHORETIC ADMINISTRATION OF MEDICATION WITH INTERNAL SENSORS |
| DE19923427A1 (en) * | 1999-05-21 | 2000-11-23 | Lohmann Therapie Syst Lts | Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow |
| AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
| US6890553B1 (en) | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
| US20030078499A1 (en) * | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
| US7133717B2 (en) * | 1999-08-25 | 2006-11-07 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery and diagnostic sampling |
| JP2004520852A (en) * | 1999-11-02 | 2004-07-15 | ユニバーシティ・オブ・ヴァーモント・アンド・ステイト・アグリカルチュアル・カレッジ | How to form micropores in the skin |
| CA2374751C (en) | 2000-03-17 | 2009-10-13 | Sontra Medical, Inc. | System, method, and device for non-invasive body fluid sampling and analysis |
| US7404815B2 (en) * | 2000-05-01 | 2008-07-29 | Lifescan, Inc. | Tissue ablation by shear force for sampling biological fluids and delivering active agents |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| AU2001288388A1 (en) * | 2000-08-24 | 2002-03-04 | Encapsulation Systems, Inc. | Substance delivery system |
| BR0114109A (en) * | 2000-09-25 | 2004-02-10 | Advanced Medical Applic Inc D | Wound treatment method and transducer for generating a liquid or powder spray |
| US6964647B1 (en) | 2000-10-06 | 2005-11-15 | Ellaz Babaev | Nozzle for ultrasound wound treatment |
| US6487447B1 (en) * | 2000-10-17 | 2002-11-26 | Ultra-Sonic Technologies, L.L.C. | Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation |
| US7914470B2 (en) | 2001-01-12 | 2011-03-29 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
| US8235919B2 (en) | 2001-01-12 | 2012-08-07 | Celleration, Inc. | Ultrasonic method and device for wound treatment |
| US6712805B2 (en) | 2001-01-29 | 2004-03-30 | Ultra Sonic Tech Llc | Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound |
| US6869618B2 (en) * | 2001-04-10 | 2005-03-22 | Kiel Laboratories, Inc. | Process for preparing tannate liquid and semi-solid dosage forms |
| US7273623B2 (en) | 2001-10-12 | 2007-09-25 | Kiel Laboratories, Inc. | Process for preparing tannate tablet, capsule or other solid dosage forms |
| NZ512367A (en) * | 2001-06-14 | 2005-05-27 | Horticulture & Food Res Inst | Non-invasive transudate extraction |
| US7135029B2 (en) | 2001-06-29 | 2006-11-14 | Makin Inder Raj S | Ultrasonic surgical instrument for intracorporeal sonodynamic therapy |
| US20050075599A1 (en) * | 2001-08-24 | 2005-04-07 | Redding Bruce K. | Ultrasonically enhanced saline treatment for burn damaged skin |
| US6908448B2 (en) * | 2001-08-24 | 2005-06-21 | Dermisonics, Inc. | Substance delivery device |
| US6509492B1 (en) | 2001-08-31 | 2003-01-21 | First Horizon Pharmaceutical Corporation | Tannate compositions and methods of treatment |
| US20030060422A1 (en) | 2001-08-31 | 2003-03-27 | Balaji Venkataraman | Tannate compositions and methods of treatment |
| AU2002346369B2 (en) | 2001-11-14 | 2009-08-27 | Eusa Pharma (Uk) Ltd | Anti-IL-6 antibodies, compositions, methods and uses |
| AU2002359576A1 (en) | 2001-12-03 | 2003-06-17 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
| TWI220386B (en) | 2002-01-21 | 2004-08-21 | Matsushita Electric Works Ltd | Ultrasonic transdermal permeation device |
| CA2478822C (en) | 2002-03-11 | 2016-07-12 | Altea Therapeutics Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| US8116860B2 (en) * | 2002-03-11 | 2012-02-14 | Altea Therapeutics Corporation | Transdermal porator and patch system and method for using same |
| US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
| WO2003086356A1 (en) * | 2002-04-09 | 2003-10-23 | Kiel Laboratories, Inc. | Diphenhydramine tannate solid dose compositions and methods of use |
| US20030233085A1 (en) | 2002-06-18 | 2003-12-18 | Pedro Giammarusti | Optimization of transcutaneous active permeation of compounds through the synergistic use of ultrasonically generated mechanical abrasion of the skin, chemical enhancers and simultaneous application of sonophoresis, iontophoresis, electroporation, mechanical vibrations and magnetophoresis through single application devices |
| AU2003280130B2 (en) | 2002-06-28 | 2009-06-11 | Centocor, Inc. | Mammalian CH1 deleted mimetibodies, compositions, methods and uses |
| US6921371B2 (en) | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
| CN1758891B (en) * | 2003-03-13 | 2012-10-10 | 自然美有限公司 | Cellulite ultrasound treatment |
| EP1622603A4 (en) * | 2003-03-25 | 2010-03-24 | Kiel Lab Inc | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| WO2004093867A2 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use |
| WO2004093866A1 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Process for preparing phenolic acid salts of gabapentin |
| KR20060041161A (en) | 2003-04-10 | 2006-05-11 | 라이트 바이오사이언스, 엘엘씨 | Photomodulation methods and devices for regulating cell proliferation and gene expression |
| US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
| US20050037979A1 (en) * | 2003-06-05 | 2005-02-17 | Ping Jeffrey H. | Tannate compositions and methods of use |
| EP1663381B1 (en) | 2003-06-13 | 2010-05-19 | The Procter & Gamble Company | Sonophoresis skin care device |
| NL1023720C2 (en) * | 2003-06-23 | 2004-12-28 | Univ Eindhoven Tech | Method for changing the transport properties of a material, method for releasing a drug from an implant, as well as implant with drug. |
| KR101160343B1 (en) * | 2003-07-31 | 2012-06-26 | 젠틀웨이브즈 엘엘씨. | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
| UA89481C2 (en) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| US20060058708A1 (en) * | 2003-12-24 | 2006-03-16 | Gill Heart | Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue |
| JP2007520285A (en) | 2004-02-06 | 2007-07-26 | バロレ，ダニエル | Method and apparatus for treating mammalian tissue |
| US20070135338A1 (en) * | 2004-03-31 | 2007-06-14 | Karyn O'neil | Human GLP-1 mimetibodies, compositions, methods and uses |
| US20080045882A1 (en) * | 2004-08-26 | 2008-02-21 | Finsterwald P M | Biological Cell Acoustic Enhancement and Stimulation |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| GB0422525D0 (en) * | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
| US20060247601A1 (en) * | 2005-04-19 | 2006-11-02 | Ellin Philip J | Method of improved drug delivery and for treatment of cellulitis |
| US20060240084A1 (en) * | 2005-04-20 | 2006-10-26 | Xylos Corporation | Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use |
| JO3058B1 (en) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
| EP1896073B1 (en) | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| JP5826450B2 (en) * | 2005-07-22 | 2015-12-02 | ザ ファウンドリー， エルエルシー | Systems and methods for delivery of therapeutic agents |
| US7655243B2 (en) | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
| US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
| US7432069B2 (en) * | 2005-12-05 | 2008-10-07 | Sontra Medical Corporation | Biocompatible chemically crosslinked hydrogels for glucose sensing |
| RS53685B1 (en) | 2005-12-29 | 2015-04-30 | Janssen Biotech Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
| EP1993670B1 (en) * | 2005-12-30 | 2012-04-18 | Sanuwave, Inc. | Acoustic pressure wave applicator system with conduction pad |
| WO2007081750A2 (en) * | 2006-01-06 | 2007-07-19 | The Curators Of The University Of Missouri | Ultrasound-mediated transcleral drug delivery |
| US7709631B2 (en) | 2006-03-13 | 2010-05-04 | Xylos Corporation | Oxidized microbial cellulose and use thereof |
| CA2648035A1 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia |
| US20070286884A1 (en) * | 2006-06-13 | 2007-12-13 | Xylos Corporation | Implantable microbial cellulose materials for hard tissue repair and regeneration |
| JP2009545368A (en) * | 2006-08-01 | 2009-12-24 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | Ultrasonic enhanced micro needle |
| US8214030B2 (en) | 2006-09-06 | 2012-07-03 | Encore Medical Asset Corporation | Iontophoresis apparatus and method |
| US7996077B2 (en) * | 2006-09-06 | 2011-08-09 | Encore Medical Asset Corporation | Iontophoresis apparatus and method |
| EP2486938B1 (en) | 2006-09-26 | 2018-05-09 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20080082039A1 (en) * | 2006-09-29 | 2008-04-03 | Eilaz Babaev | Ultrasound Liquid Delivery Device |
| US8050752B2 (en) * | 2006-09-29 | 2011-11-01 | Bacoustics, Llc | Method of treating lumens, cavities, and tissues of the body with an ultrasound delivered liquid |
| US8010188B2 (en) * | 2006-11-14 | 2011-08-30 | Kagoshima University | Drug injecting device |
| AR064623A1 (en) * | 2006-12-21 | 2009-04-15 | Centocor Inc | USE OF LONG-TERM GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES |
| US8491521B2 (en) | 2007-01-04 | 2013-07-23 | Celleration, Inc. | Removable multi-channel applicator nozzle |
| US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
| US8386027B2 (en) | 2007-04-27 | 2013-02-26 | Echo Therapeutics, Inc. | Skin permeation device for analyte sensing or transdermal drug delivery |
| US9044568B2 (en) | 2007-06-22 | 2015-06-02 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
| US20090062724A1 (en) * | 2007-08-31 | 2009-03-05 | Rixen Chen | System and apparatus for sonodynamic therapy |
| US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| US20090216178A1 (en) * | 2008-02-26 | 2009-08-27 | Lee Susan J | Method And Apparatus For Preventing Localized Stasis Of Cerebrospinal Fluid |
| EP2529686B1 (en) | 2008-05-09 | 2015-10-14 | Holaira, Inc. | System for treating a bronchial tree |
| US20090318852A1 (en) * | 2008-06-18 | 2009-12-24 | Jenu Biosciences, Inc. | Ultrasound based cosmetic therapy method and apparatus |
| WO2010017177A1 (en) * | 2008-08-06 | 2010-02-11 | The Trustees Of The University Of Pennsylvania | Ultrasonically induced release from polymer vesicles |
| WO2010017598A1 (en) | 2008-08-14 | 2010-02-18 | Arana Therapeutics Limited | Anti-il-12/il-23 antibodies |
| MX2011004550A (en) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Fibronectin type iii domain based scaffold compositions, methods and uses. |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| TWI494125B (en) | 2009-06-05 | 2015-08-01 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants |
| US9649153B2 (en) | 2009-10-27 | 2017-05-16 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
| CA2780608C (en) | 2009-11-11 | 2019-02-26 | Innovative Pulmonary Solutions, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
| US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
| WO2011098518A2 (en) | 2010-02-11 | 2011-08-18 | Ablynx Nv | Delivery of immunoglobulin variable domains and constructs thereof |
| ES2961381T3 (en) | 2010-06-19 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| WO2012129545A1 (en) | 2011-03-23 | 2012-09-27 | Redding Bruce K | Systems and methods for enhancing the delivery of compounds to skin pores using ultrasonic waveforms |
| JP6054942B2 (en) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | Immunogenic compositions and methods of using the compositions to elicit humoral and cellular immune responses |
| US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
| BR112014028476A2 (en) | 2012-05-16 | 2017-08-01 | Immune Design Corp | immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject |
| AU2013262630B2 (en) | 2012-05-18 | 2017-11-16 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US20140066837A1 (en) | 2012-07-26 | 2014-03-06 | Ronald L. Moy | Skin care compositions and methods |
| EP2732832A3 (en) | 2012-11-14 | 2015-07-01 | Universitair Medisch Centrum Groningen (UMCG) | Drug delivery device comprising an active compound and a thermo-sensitive polymeric material |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| CA2903576C (en) | 2013-03-15 | 2021-06-08 | Nai-Kong V. Cheung | High affinity anti-gd2 antibodies |
| EA032326B1 (en) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| US9624280B2 (en) | 2013-10-03 | 2017-04-18 | Janssen Biotech, Inc. | Protoxin-II variants and methods of use |
| AU2014355072A1 (en) | 2013-11-26 | 2016-06-02 | Alliqua Biomedical, Inc. | Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing |
| AU2015209575A1 (en) | 2014-01-21 | 2016-07-21 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
| US10273311B2 (en) | 2014-06-26 | 2019-04-30 | Yale University | Compositions to regulate renalase in the treatment of diseases and disorders |
| MA41642A (en) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | PROTOXIN II VARIANTS AND METHODS OF USE |
| CA2981336A1 (en) | 2015-04-02 | 2016-10-06 | Janssen Biotech, Inc. | Protoxin-ii variants and methods of use |
| EP3307388B1 (en) | 2015-06-10 | 2022-06-22 | Ekos Corporation | Ultrasound catheter |
| WO2017079764A1 (en) * | 2015-11-06 | 2017-05-11 | Bkr Ip Holdco Llc | Method for the attenuation enhancement of absorbent materials used in both passive and active transdermal drug delivery systems |
| WO2017172771A2 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
| MX2018013640A (en) | 2016-05-16 | 2019-08-01 | Infectious Disease Res Inst | Pegylated liposomes and methods of use. |
| CN109310773B (en) | 2016-05-16 | 2022-04-26 | 传染病研究所 | Formulations containing TLR agonists and methods of use |
| AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
| EP3484927A1 (en) | 2016-07-15 | 2019-05-22 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
| JP2019524721A (en) | 2016-07-15 | 2019-09-05 | ポセイダ セラピューティクス， インコーポレイテッド | Chimeric antigen receptor and method of use |
| CA3037961A1 (en) | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
| KR20190078648A (en) | 2016-11-16 | 2019-07-04 | 얀센 바이오테크 인코포레이티드 | Methods for treating psoriasis with anti-IL23 specific antibodies |
| EP3573658A4 (en) | 2017-01-30 | 2021-07-21 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| JP2020506947A (en) | 2017-02-07 | 2020-03-05 | ヤンセン バイオテツク，インコーポレーテツド | Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis |
| CA3066915A1 (en) | 2017-06-11 | 2018-12-20 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
| EP3679145A2 (en) | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
| TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
| JP2021507703A (en) | 2017-12-20 | 2021-02-25 | ポセイダ セラピューティクス，インコーポレイティド | VCAR composition and its usage |
| KR20200129125A (en) | 2018-03-05 | 2020-11-17 | 얀센 바이오테크 인코포레이티드 | How to treat Crohn's disease with anti-IL23 specific antibodies |
| WO2019173636A1 (en) | 2018-03-07 | 2019-09-12 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
| US20190345245A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
| SI3883606T1 (en) | 2018-09-24 | 2023-10-30 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| US11548941B2 (en) | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
| EP3897722A4 (en) | 2018-12-18 | 2022-09-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| CA3124103A1 (en) | 2018-12-20 | 2020-06-25 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| EP3911676A1 (en) | 2019-01-15 | 2021-11-24 | Janssen Biotech, Inc. | Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
| KR20210118878A (en) | 2019-01-23 | 2021-10-01 | 얀센 바이오테크 인코포레이티드 | Anti-TNF antibody composition for use in a method of treating psoriatic arthritis |
| MA55283A (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS |
| JP2022525145A (en) | 2019-03-14 | 2022-05-11 | ヤンセン バイオテツク，インコーポレーテツド | A production method for producing an anti-IL12 / IL23 antibody composition. |
| KR20210141998A (en) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | Method of making anti-TNF antibody composition |
| MA55282A (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS |
| EA202192459A1 (en) | 2019-03-18 | 2021-11-25 | Янссен Байотек, Инк. | METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN |
| KR20220012883A (en) | 2019-05-23 | 2022-02-04 | 얀센 바이오테크 인코포레이티드 | A method of treating inflammatory bowel disease with a combination therapy of IL-23 and an antibody against TNF alpha |
| EP3976648A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
| CA3142580A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
| WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
| US20220372105A1 (en) | 2019-09-05 | 2022-11-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CA3162246A1 (en) | 2019-12-20 | 2021-06-24 | Poseida Therapeutics, Inc. | Anti-muc1 compositions and methods of use |
| US20230104091A1 (en) | 2020-03-04 | 2023-04-06 | Poseida Therapeutics, Inc. | Compositions and methods for the treatment of metabolic liver disorders |
| WO2021183795A1 (en) | 2020-03-11 | 2021-09-16 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| CN115996747A (en) | 2020-04-14 | 2023-04-21 | 波赛达治疗公司 | Compositions and methods for treating cancer |
| WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
| WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
| US20240000969A1 (en) | 2020-10-21 | 2024-01-04 | Poseida Therapeutics San Diego | Compositions and methods for delivery of nucleic acids |
| CN117120087A (en) | 2020-12-23 | 2023-11-24 | 高级健康研究所 | Solanesol vaccine adjuvant and its preparation method |
| US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| EP4297728A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| EP4301863A1 (en) | 2021-03-04 | 2024-01-10 | Poseida Therapeutics, Inc. | Compositions and methods for the treatment of hemophilia |
| CA3212729A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| AU2022232007A1 (en) | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| US20230038355A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
| WO2023281462A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| KR20240032991A (en) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
| WO2023041985A2 (en) | 2021-09-15 | 2023-03-23 | New York University In Abu Dhabicorporation | Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof |
| WO2023060088A1 (en) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
| WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
| WO2023141576A1 (en) | 2022-01-21 | 2023-07-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2023164573A1 (en) | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
| WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
| WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
| WO2024036273A1 (en) | 2022-08-11 | 2024-02-15 | Poseida Therapeutics, Inc. | Chimeric cd8-alpha co-receptor compositions and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU445433A1 (en) * | 1973-03-22 | 1974-10-05 | Центральный Научно-Исследовательский Институт Курортологии И Физиотерапии | The method of physiotherapeutic treatment of patients with diseases of the musculoskeletal system of an exchange nature |
| SU506421A1 (en) * | 1974-08-06 | 1978-03-05 | Московское Ордена Ленина И Ордена Трудового Красного Знамени Высшее Техническое Училище Имени Н.Э.Баумана | Method of treating infected wounds |
| US4127125A (en) * | 1975-12-22 | 1978-11-28 | Lion Hamigaki Kabushiki Kaisha | Devices for transmitting ultrasonic waves to teeth |
| SU556805A1 (en) * | 1976-01-23 | 1977-05-05 | Каунасский Медицинский Институт | Method of administering drugs |
| US4309989A (en) * | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| GB1577551A (en) * | 1976-02-09 | 1980-10-22 | Fahim M | Medication for topical application by ultrasound |
| SU591186A1 (en) * | 1976-07-23 | 1978-02-05 | Serov Vilenin Nikolaevich | Method of treating eye diseases |
| US4176664A (en) * | 1978-03-13 | 1979-12-04 | Stanley Kalish | Impregnated bandage |
| US4280494A (en) * | 1979-06-26 | 1981-07-28 | Cosgrove Robert J Jun | System for automatic feedback-controlled administration of drugs |
| SU910157A1 (en) * | 1980-02-29 | 1982-03-07 | Московское Ордена Ленина,Ордена Трудового Красного Знамени Высшее Техническое Училище Им.Баумана | Method of treating infected wounds |
| US4372296A (en) * | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
| JPS5995060A (en) * | 1982-11-24 | 1984-05-31 | 嶋田 昭雄 | Dermatophytosis treating device |
| US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
-
1986
- 1986-07-08 US US06/883,111 patent/US4767402A/en not_active Expired - Lifetime
-
1987
- 1987-06-29 WO PCT/US1987/001546 patent/WO1988000001A2/en not_active Application Discontinuation
- 1987-06-29 JP JP62504399A patent/JP2710281B2/en not_active Expired - Lifetime
- 1987-06-29 EP EP87904765A patent/EP0275284A1/en not_active Withdrawn
- 1987-07-07 CA CA000541496A patent/CA1324051C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8287483B2 (en) | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
| US8870810B2 (en) | 1998-12-18 | 2014-10-28 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
| US8224414B2 (en) | 2004-10-28 | 2012-07-17 | Echo Therapeutics, Inc. | System and method for analyte sampling and analysis with hydrogel |
| US8812071B2 (en) | 2007-03-07 | 2014-08-19 | Echo Therapeutics, Inc. | Transdermal analyte monitoring systems and methods for analyte detection |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988000001A2 (en) | 1988-01-14 |
| US4767402A (en) | 1988-08-30 |
| JP2710281B2 (en) | 1998-02-10 |
| EP0275284A1 (en) | 1988-07-27 |
| JPH01500247A (en) | 1989-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1324051C (en) | Ultrasound enhancement of transdermal drug delivery | |
| Boucaud et al. | In vitro study of low-frequency ultrasound-enhanced transdermal transport of fentanyl and caffeine across human and hairless rat skin | |
| Levy et al. | Effect of ultrasound on transdermal drug delivery to rats and guinea pigs. | |
| JP2695986B2 (en) | Delivery of substances through ultrasound-enhanced skin | |
| US4948587A (en) | Ultrasound enhancement of transbuccal drug delivery | |
| EP0398960B1 (en) | Transport of molecules across tissue using electroporation | |
| US6018678A (en) | Transdermal protein delivery or measurement using low-frequency sonophoresis | |
| US6190315B1 (en) | Sonophoretic enhanced transdermal transport | |
| Mitragotri et al. | Low-frequency sonophoresis: a review | |
| Nanda et al. | Current developments using emerging transdermal technologies in physical enhancement methods. | |
| Bommannan et al. | Sonophoresis. I. The use of high-frequency ultrasound to enhance transdermal drug delivery | |
| US5617851A (en) | Ultrasonic transdermal system for withdrawing fluid from an organism and determining the concentration of a substance in the fluid | |
| JP2953625B2 (en) | Method for reducing skin irritation associated with drug / penetration enhancing compositions | |
| US6620123B1 (en) | Method and apparatus for producing homogenous cavitation to enhance transdermal transport | |
| KR100636460B1 (en) | Device and method for increasing the transdermal permeation of medicaments | |
| US20040210184A1 (en) | Effect of electric field and ultrasound for transdermal drug delivery | |
| KR20010040785A (en) | Pressure sensitive adhesive matrix patch for the treatment of onychomycosis | |
| Ronnander et al. | Transdermal delivery of sumatriptan succinate using iontophoresis and dissolving microneedles | |
| Comaish et al. | Site of action of methotrexate in psoriasis | |
| Barry | Penetration enhancer classification | |
| Svedman et al. | Passive drug diffusion via standardized skin mini-erosion; methodological aspects and clinical findings with new device | |
| AU768190B2 (en) | Method and apparatus for producing homogenous cavitation to enhance transdermal transport | |
| US4677968A (en) | Methods of testing the reaction of various substances on living human skin | |
| Escribano et al. | Rapid human skin permeation and topical anaesthetic activity of a new amethocaine microemulsion | |
| Xie et al. | Detection of Transdermal Drug Delivery Efficiency by Shock Wave |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed | ||
| MKEC | Expiry (correction) |
Effective date: 20121205 |